Eupraxia Pharmaceuticals announced positive 36-week data from its EP-104GI treatment for Eosinophilic Esophagitis, showing robust tissue health improvements. The company completed a $63.2 million public offering to fund further clinical trials and expand indications. With over $140 million in cash and investments, Eupraxia is well-funded into the second half of 2028, supporting ongoing and new clinical programs. Management continues to monitor trade tariffs but expects minimal impact on operations.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UniFirst Corporation has been recognized on Selling Power's 60 Best Companies to Sell For list for the 23rd consecutive year, highlighting its strong sales culture and support for sales professionals. The list evaluates companies on compensation, tra...
Traders on Polymarket have significantly reduced their bets on a Tesla-SpaceX merger announcement this year, with the chance of a deal by September 30 now at 11%, down 28 points, and by December 31 at 24%, down 19 points. This decline contrasts with ...
Brazil Potash Corp. disclosed a procedural filing by the Brazilian Federal Public Defender’s Office seeking to suspend activities at its Autazes potash project. The filing challenges prior favorable court decisions but does not introduce new facts or...
DT Midstream, Inc. will announce its financial results for the second quarter of 2026 before the market opens on July 30, 2026. The company has scheduled a conference call at 9:00 a.m. ET on the same day to discuss the results. Investors and the publ...
